DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1951)

Atopic Dermatitis/Atopic Eczema | Unmet Need | Detailed, Expanded Analysis: Pediatric (US & EU)

Atopic Dermatitis/Atopic Eczema | Unmet Need | Detailed, Expanded Analysis: Pediatric (US & EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The management of pediatric patients with moderate to severe atopic dermatitis (AD) is poised for transformation. Sanofi/Regeneron’s Dupixent, on the heels of a positive Phase III study in adolescent patients, appears set to gain expanded approval in this population beginning in 2019, and the late-stage pipeline features compelling programs, including Pfizer’s abrocitinib and AbbVie’s upadacitinib. Pediatric patients comprise a sizable percentage of the AD population, and clinicians appear to manage them with a risk tolerance that is lower than accepted in adult patients. We will assess the commercial opportunity in the pediatric, topical-refractory, moderate to severe AD space through a comprehensive look at the key efficacy, safety, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the appeal of potential AD products in the pediatric population.

QUESTIONS ANSWERED

  • How do surveyed dermatologists rate the performance of current therapies (e.g., Sanofi/Regeneron’s Dupixent, cyclosporine) on attributes including effect on eczema, effect on itch, safety/tolerability, delivery, and nonclinical factors?
  • What are the most compelling unmet treatment needs that would drive positive differentiation in this arena (e.g., fast onset of action)? How well poised are pipeline agents (e.g., Pfizer’s abrocitinib, AbbVie’s upadacitinib) to capitalize on them?
  • What trade-offs between clinical attributes and price will clinicians accept when considering whether to prescribe a hypothetical AD target product profile?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European dermatologists treating pediatric patients

Key companies: Sanofi, Regeneron, Pfizer, AbbVie, LEO Pharma, Eli Lilly, Incyte, Vanda, Novartis, Galderma, Dermira

Key drugs: Dupixent, cyclosporine, methotrexate, azathioprine, mycophenolate, oral prednisone

KEY METRICS INCLUDED

  • Target Product Profile (TPP) simulator based on conjoint analysis methodology
  • Stated versus derived importance of product attributes on prescribing behavior
  • Assessment of current drug performance against treatment drivers and goals
  • Physician perceptions of unmet needs in the indication and related indications
  • Analysis of remaining
  • Drug development opportunities

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis: Pediatric (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Topical-Refractory Moderate to Severe Pediatric Atopic Dermatitis
      • Key Findings: Unmet Need in Topical-Refractory Moderate to Severe Pediatric Atopic Dermatitis and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Topical Refractory, Moderate to Severe Pediatric Atopic Dermatitis Market and Emerging Therapy Insights
        • Opportunity: Therapies That Are More Effective in Clearing Eczema
        • Opportunity: Therapies That Are More Effective in Reducing Itch
        • Opportunity: Additional Effective Therapies That Have Good Safety and Tolerability Profiles
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Topical-Refractory Moderate to Severe Pediatric Atopic Dermatitis Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: May 2019
  • Author(s): Laura Darnieder
  • Laura Darnieder is a Business Insights Analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, where she is focused on providing market forecasts within the niche biopharmaceutical space. Prior to joining DRG, Laura earned a in Neuroscience from Tufts University Sackler School of Graduate Biomedical Sciences. Her research focused on the role of stress neuropeptides and inhibitory signaling in alcohol dependence and drug addiction. She also holds a , summa cum laude, in Psychobiology and Linguistics from Binghamton University (SUNY).

Purchase Report

Recent reports:
You may also be interested in: